Bicycle Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	72.59	35.28	26.98	14.46	11.7
Revenue Growth (YoY)	105.77%	30.76%	86.52%	23.65%	12.58%
Cost of Revenue	229.08	164.86	147.65	81.61	44.88
Gross Profit	-156.5	-129.59	-120.68	-67.15	-33.18
Selling, General & Admin	86.37	79.19	69.27	49.51	32.44
Operating Expenses	86.37	79.19	69.27	49.51	32.44
Operating Income	-242.87	-208.77	-189.95	-116.65	-65.62
Interest Expense	-0.21	-1.73	-3.26	-3.34	-2.98
Interest & Investment Income	28.46	34.28	14	5.76	0.12
EBT Excluding Unusual Items	-214.61	-176.22	-179.21	-114.24	-68.48
Other Unusual Items	-4.2	2.42	-	-	-
Pretax Income	-218.81	-173.8	-179.21	-114.24	-68.48
Income Tax Expense	0.15	-4.77	1.46	-1.52	-1.66
Net Income	-218.96	-169.03	-180.66	-112.72	-66.82
Net Income to Common	-218.96	-169.03	-180.66	-112.72	-66.82
Shares Outstanding (Basic)	69	58	36	30	25
Shares Outstanding (Diluted)	69	58	36	30	25
Shares Change (YoY)	19.02%	63.54%	20.00%	18.35%	30.90%
EPS (Basic)	-3.16	-2.90	-5.08	-3.80	-2.67
EPS (Diluted)	-3.16	-2.90	-5.08	-3.80	-2.67
Free Cash Flow	-252.03	-165.96	-63.56	-105.1	-16.82
Free Cash Flow Per Share	-3.64	-2.85	-1.79	-3.54	-0.67
Gross Margin	-215.60%	-	-	-	-283.69%
Operating Margin	-334.59%	-591.84%	-704.13%	-806.56%	-560.98%
Profit Margin	-301.66%	-479.18%	-669.72%	-779.35%	-571.25%
Free Cash Flow Margin	-347.21%	-470.47%	-235.61%	-726.67%	-143.83%
EBITDA	-236.44	-201.6	-183.4	-112.96	-64.21
D&A For EBITDA	6.42	7.17	6.55	3.69	1.41
EBIT	-242.87	-208.77	-189.95	-116.65	-65.62

Updated Mar 17, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q